Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P

Chemotherapy

Volumn 48, Issue 4-5, 2002, Pages 224-231

  Carrillo Muñoz, Alfonso Javier ^a   Ruesga, Maite ^b   Brio, Sonia ^a   Del Valle, Oscar ^c   Rodriguez, Virginia ^c   Santos, Patricia ^g   Hernández Molina, Juan Manuel ^d   Cantón, Emilia ^e   Pemán, Javier ^e   Guarro, Josep ^f   Quindós, Guillermo ^b  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL LA INMACULADA   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^g Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Amphotericin B; Amphotericin B lipid complex; Antifungal agent; Fungi; Itraconazole; Susceptibility

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ITRACONAZOLE;

ANALYTIC METHOD; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL CELL; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PRIORITY JOURNAL; RHODOTORULA; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM APIOSPERMUM; TRICHOSPORON BEIGELII; TRICHOSPORON CUTANEUM; YARROWIA LIPOLYTICA; IN VITRO STUDY; LABORATORY TEST; SCEDOSPORIUM; YEAST;

EID: 12244281867     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066764     Document Type: Article

References (40)

1. Viscoli C, Castagnola E: Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review. Int J Infect Dis 1998;3:109-118.
2. Dix SP, Wingard JR: Amphotericin B lipid complex: Review of safety, pharmacokinetics and efficacy. Drugs Today 1996;32(suppl G):19-25.
3. Fortún J, Cobo J, Pozuelo MJ: Liposomal amphotericin B. General features, therapeutical indications and clinical experience. Rev Iberoam Micol 1994;11:111-115.
4. de Marie S, Janknegt R, Bakker-Woudenberg IA: Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-916.
5. de Marie S: Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996;10(suppl 2):S93-S96.
6. Fromtling RA: Amphotericin B lipid complex. Drugs Future 1995;20:129-134.
7. Fromtling RA: Experimental and clinical pharmacokinetics of amphotericin B lipid complex. Drugs Today 1996;32(suppl G):9-17.
8. Janoff AS, Perkins WR, Saletan SL, Swenson CE: Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:389-451.
9. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey G: Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1981;10:665-668.
10. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW: Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998;42:1412-1416.
11. Mitsutake K, Hohno S, Miyazaki Y: In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 1994;128:13-17.
12. Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga MT, Miranda Y, del Valle O, Cossum PA, Wallace TL: In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 41:397-401.
13. Quindós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, Ruesga MT, Pemán J, Valverde A, Canton E, Martin-Mazuelos E, Pontón J: In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000;46:395-401.
14. Jessup C, Reyes G, Fothergill A, McCarthy D, Rinaldi M, Messer S, Pfaller M, Ghannoum M: A head-on comparison of conventional and lipid-based amphotericin B: A multicenter study. Chemotherapy 2000;12:22-29.
15. Carrillo-Muñoz AJ, Quindó s G, del Valle O, Rodríguez V, Arévalo MP, Salgado J, Martín-Mazuelos E, Bornay-Llinares FJ, del Palacio A, Cuétara M, Gasser I, Hernández-Molina JM, Pemán J, Ruesga M, Alonso R: Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy 2000;46:235-244.
16. Hopfer RL, Mills K, Metha R, López-Berestein G, Fainstein V, Juliano RL: In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 1994;25:387-389.
17. Legrand P, Cheron M, Leroy L, Bolard J: Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Target 1997;4:311-319.
18. Arikan S, Rex JH: Lipid-based antifungal agents: Current status. Curr Pharm Des 2001;7:393-415.
19. Bailey EM, Krakosky DJ, Rybak MJ: The triazole antifungal agents: A review of itraconazole and fluconazole. Pharmacotherapy 1990;10:147-153.
20. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woesternborghs R, Van Cutsem J, Cauwenbergh G: The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989;32(suppl 1):67-87.
21. Van Cutsem J: Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals. Mycoses 1989;32(suppl 1):14-34.
22. Barone JA, Moskovitz BL, Guarnieri J, et al: Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1989;42:1862-1865.
23. Miyake K, Irie T, Arima H, et al: Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int J Pharm 1999;179:237-245.
24. Phillips P, Zemcov J, Mahmood W, Montaner JS, Craib K, Clarke AM: Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro susceptibility. AIDS 1996;10:1369-1376.
25. Piérard GE, Arrese JE, Piérard-Franchimont C: Itraconazole. Expert Opin Pharmacother 2000;1:287-304.
26. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard NCCLS Document M27-A. Wayne, National Committee for Clinical Laboratory Standards, 1997.
27. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi. Proposed Standard M38-P. Wayne, National Committee for Clinical Laboratory Standards, 1998.
28. Fernández-Torres B, Carrillo AJ, del Palacio A, Moore MK, Valverde A, Serrano M, Guarro J: In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001;45:2524-2528.
29. Espinel-Ingroff A: In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-958.
30. Espinel-Ingroff A, Bartlett M, Chaturvedi V, Ghannoum M, Hazen KC, Pfaller MA, Rinalid M, Walsh TJ: Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLs collaborative evaluation. Antimicrob Agents Chemother 2001;45:1828-1835.
31. Rex JH, Pfaller MA, Rinalid MG, Polak AM, Galgiani JN: Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-381.
32. Espinel-Ingroff A: Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioter 2000;13:161-166.
33. Odds FC: Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? Rev Iberoam Micol 1998;14:83-84.
34. Odds FC: Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resist Updat 1998;1:11-15.
35. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL: Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997;24:235-247
36. Legrand P, Cheron M, Leroy L, Bolard J: Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Target 1997;4:311-319.
37. Espinel-Ingroff A, Shadomy S, Gebhart RJ: In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother 1984;26:5-9.
38. Odds FC, Van Gerven F, Espinal-Ingroff A, Bartlett MS, Ghannoum MA, Lancaster MV, Pfaller MA, Rex JH, Rinaldi MG, Walsh TJ: Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998;42:282-288.
39. Oakley KA, Moore CB, Denning DW: Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex and itraconazole. Antimicrob Agents Chemother 1999;43:1264-1266.
40. Espinel-Ingroff A: Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole and voriconazole. Antimicrob Agents Chemother 2001;45:605-607.